Research ExplorerPublicationsEffect of periprocedural furosemide-induced diuresis with ma...

Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation

Standard

Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation. / Voigtländer-Buschmann, Lisa; Schäfer, Sarina; Schmidt-Lauber, Christian; Weimann, Jessica; Shenas, Mina; Giraldo Cortes, Julian; Kuta, Piotr Mariusz; Zeller, Tanja; Twerenbold, Raphael; Seiffert, Moritz; Schofer, Niklas; Schneeberger, Yvonne; Schäfer, Andreas; Schirmer, Johannes; Reichenspurner, Hermann; Blankenberg, Stefan; Conradi, Lenard; Schäfer, Ulrich.

In: CLIN RES CARDIOL, Vol. 113, No. 6, 06.2024, p. 801-811.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Voigtländer-Buschmann, L, Schäfer, S, Schmidt-Lauber, C, Weimann, J, Shenas, M, Giraldo Cortes, J, Kuta, PM, Zeller, T, Twerenbold, R, Seiffert, M, Schofer, N, Schneeberger, Y, Schäfer, A, Schirmer, J, Reichenspurner, H, Blankenberg, S, Conradi, L & Schäfer, U 2024, 'Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation', CLIN RES CARDIOL, vol. 113, no. 6, pp. 801-811. https://doi.org/10.1007/s00392-023-02234-z

APA

Voigtländer-Buschmann, L., Schäfer, S., Schmidt-Lauber, C., Weimann, J., Shenas, M., Giraldo Cortes, J., Kuta, P. M., Zeller, T., Twerenbold, R., Seiffert, M., Schofer, N., Schneeberger, Y., Schäfer, A., Schirmer, J., Reichenspurner, H., Blankenberg, S., Conradi, L., & Schäfer, U. (2024). Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation. CLIN RES CARDIOL, 113(6), 801-811. https://doi.org/10.1007/s00392-023-02234-z

Vancouver

Voigtländer-Buschmann L, Schäfer S, Schmidt-Lauber C, Weimann J, Shenas M, Giraldo Cortes J et al. Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation. CLIN RES CARDIOL. 2024 Jun;113(6):801-811. https://doi.org/10.1007/s00392-023-02234-z

Bibtex

@article{d43c30d20ecc46488613de5dbcb358fc,
title = "Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation",
abstract = "BACKGROUND: Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is a serious complication which is associated with increased mortality. The RenalGuard system was developed to reduce the risk of AKI after contrast media exposition by furosemide-induced diuresis with matched isotonic intravenous hydration. The aim of this study was to examine the effect of the RenalGuard system on the occurrence of AKI after TAVI in patients with chronic kidney disease.METHODS: The present study is a single-center randomized trial including patients with severe aortic valve stenosis undergoing TAVI. Overall, a total of 100 patients treated by TAVI between January 2017 and August 2018 were randomly assigned to a periprocedural treatment with the RenalGuard system or standard treatment by pre- and postprocedural intravenous hydration. Primary endpoint was the occurrence of AKI after TAVI, and secondary endpoints were assessed according to valve academic research consortium 2 criteria.RESULTS: Overall, the prevalence of AKI was 18.4% (n = 18). The majority of these patients developed mild AKI according to stage 1. Comparing RenalGuard to standard therapy, no significant differences were observed in the occurrence of AKI (RenalGuard: 21.3%; control group: 15.7%; p = 0.651). In addition, there were no differences between the groups with regard to 30-day and 12-month mortality and procedure-associated complication rates.CONCLUSION: In this randomized trial, we did not detect a reduction in AKI after TAVI by using the RenalGuard system. A substantial number of patients with chronic kidney disease developed AKI after TAVI, whereas the majority presented with mild AKI according to stage 1 (ClinicalTrials.gov number NCT04537325).",
author = "Lisa Voigtl{\"a}nder-Buschmann and Sarina Sch{\"a}fer and Christian Schmidt-Lauber and Jessica Weimann and Mina Shenas and {Giraldo Cortes}, Julian and Kuta, {Piotr Mariusz} and Tanja Zeller and Raphael Twerenbold and Moritz Seiffert and Niklas Schofer and Yvonne Schneeberger and Andreas Sch{\"a}fer and Johannes Schirmer and Hermann Reichenspurner and Stefan Blankenberg and Lenard Conradi and Ulrich Sch{\"a}fer",
note = "{\textcopyright} 2023. The Author(s).",
year = "2024",
month = jun,
doi = "10.1007/s00392-023-02234-z",
language = "English",
volume = "113",
pages = "801--811",
journal = "CLIN RES CARDIOL",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "6",

}

RIS

TY - JOUR

T1 - Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation

AU - Voigtländer-Buschmann, Lisa

AU - Schäfer, Sarina

AU - Schmidt-Lauber, Christian

AU - Weimann, Jessica

AU - Shenas, Mina

AU - Giraldo Cortes, Julian

AU - Kuta, Piotr Mariusz

AU - Zeller, Tanja

AU - Twerenbold, Raphael

AU - Seiffert, Moritz

AU - Schofer, Niklas

AU - Schneeberger, Yvonne

AU - Schäfer, Andreas

AU - Schirmer, Johannes

AU - Reichenspurner, Hermann

AU - Blankenberg, Stefan

AU - Conradi, Lenard

AU - Schäfer, Ulrich

N1 - © 2023. The Author(s).

PY - 2024/6

Y1 - 2024/6

N2 - BACKGROUND: Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is a serious complication which is associated with increased mortality. The RenalGuard system was developed to reduce the risk of AKI after contrast media exposition by furosemide-induced diuresis with matched isotonic intravenous hydration. The aim of this study was to examine the effect of the RenalGuard system on the occurrence of AKI after TAVI in patients with chronic kidney disease.METHODS: The present study is a single-center randomized trial including patients with severe aortic valve stenosis undergoing TAVI. Overall, a total of 100 patients treated by TAVI between January 2017 and August 2018 were randomly assigned to a periprocedural treatment with the RenalGuard system or standard treatment by pre- and postprocedural intravenous hydration. Primary endpoint was the occurrence of AKI after TAVI, and secondary endpoints were assessed according to valve academic research consortium 2 criteria.RESULTS: Overall, the prevalence of AKI was 18.4% (n = 18). The majority of these patients developed mild AKI according to stage 1. Comparing RenalGuard to standard therapy, no significant differences were observed in the occurrence of AKI (RenalGuard: 21.3%; control group: 15.7%; p = 0.651). In addition, there were no differences between the groups with regard to 30-day and 12-month mortality and procedure-associated complication rates.CONCLUSION: In this randomized trial, we did not detect a reduction in AKI after TAVI by using the RenalGuard system. A substantial number of patients with chronic kidney disease developed AKI after TAVI, whereas the majority presented with mild AKI according to stage 1 (ClinicalTrials.gov number NCT04537325).

AB - BACKGROUND: Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is a serious complication which is associated with increased mortality. The RenalGuard system was developed to reduce the risk of AKI after contrast media exposition by furosemide-induced diuresis with matched isotonic intravenous hydration. The aim of this study was to examine the effect of the RenalGuard system on the occurrence of AKI after TAVI in patients with chronic kidney disease.METHODS: The present study is a single-center randomized trial including patients with severe aortic valve stenosis undergoing TAVI. Overall, a total of 100 patients treated by TAVI between January 2017 and August 2018 were randomly assigned to a periprocedural treatment with the RenalGuard system or standard treatment by pre- and postprocedural intravenous hydration. Primary endpoint was the occurrence of AKI after TAVI, and secondary endpoints were assessed according to valve academic research consortium 2 criteria.RESULTS: Overall, the prevalence of AKI was 18.4% (n = 18). The majority of these patients developed mild AKI according to stage 1. Comparing RenalGuard to standard therapy, no significant differences were observed in the occurrence of AKI (RenalGuard: 21.3%; control group: 15.7%; p = 0.651). In addition, there were no differences between the groups with regard to 30-day and 12-month mortality and procedure-associated complication rates.CONCLUSION: In this randomized trial, we did not detect a reduction in AKI after TAVI by using the RenalGuard system. A substantial number of patients with chronic kidney disease developed AKI after TAVI, whereas the majority presented with mild AKI according to stage 1 (ClinicalTrials.gov number NCT04537325).

U2 - 10.1007/s00392-023-02234-z

DO - 10.1007/s00392-023-02234-z

M3 - SCORING: Journal article

C2 - 37264143

VL - 113

SP - 801

EP - 811

JO - CLIN RES CARDIOL

JF - CLIN RES CARDIOL

SN - 1861-0684

IS - 6

ER -